[Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].

Objective: To examine the efficacy and safety of endothelin receptor antagonists (ERA) combined with phosphodiesterase 5 inhibitors (PDE5i) in the treatment of pulmonary artery hypertension (PAH). Methods: Computer-based retrieval was performed on PubMed, Cochrane Library, CNKI, Wanfang, and VIP database (up to February 12th, 2021). Randomized controlled trials about endothelin receptor antagonists (ERAs) or PDE5i in patients with PAH were collected. The change of 6-minute walking distance (6MWD) in 12-16 weeks was used as primary outcome index. Case fatality rate, worsening clinical events, WHO functional class (FC) improvement, adverse events (AEs), serious adverse events (SAE) were the key secondary outcomes indicators. STATA 16.0 software was used for network meta-analysis, and the pooled estimates of odds ratios ( OR s) or weighted mean differences (WMDs) and 95% confidence intervals ( CI s) of the results were shown. To help explain OR s and WMDs, we used the surface under the cumulative ranking curve (SUCRA) to calculate the probability of each intervention. Results: We included 29 trials with 5 949 participants. In network meta-analysis, Bosentan combined with Sildenafil ( WMD =53.93, 95% CI =6.19-101.66) had shown the greatest improvement in 6MWD compared with placebo, followed by Bosentan combined with Tadalafil ( WMD =50.84, 95% CI =7.05-94.62), Ambrisentan combined with Tadalafil ( WMD =46.67, 95% CI =15.88-77.45), Bosentan ( WMD =29.44, 95% CI =5.86-53.02), Ambrisentan ( WMD =23.90, 95% CI =0.31-47.48) and Macitentan ( WMD =21.57, 95% CI =2.45-40.69). According to SUCRA, the effects of different intervention measures on improving 6MWD in patients with arterial pulmonary hypertension were as follows: Bosentan+Sildenafil (82.9%)>Bosentan+Tadalafil (78.4%)>Ambrisentan+Tadalafil (77.1%)>Bosentan (49.2%)>Sildenafil (48.5%)>Ambrisentan (40.3%)>Macitentan (37.3%)>Tadalafil (33.0%)>Placebo (3.3%). For the WHO functional class, Sildenafil ( OR =2.90, 95% CI =1.04-8.08) was optimal compared with placebo, followed by Bosentan ( OR =2.15, 95% CI =1.15-4.04), and there was no significant difference in the rest. For clinical worsening, Bosentan combined with Tadalafil ( OR =0.08, 95% CI =0.01-0.49) performed best compared with placebo, followed by Bosentan ( OR =0.20, 95% CI =0.11-0.38), Bosentan combined with Sildenafil ( OR =0.21, 95% CI =0.09-0.46), Ambrisentan combined with Tadalafil ( OR =0.27, 95% CI =0.15-0.50), Sildenafil ( OR =0.33, 95% CI =0.17-0.66) and Tadalafil ( OR =0.44, 95% CI =0.21-0.90). There was no statistical difference between all interventions and placebo in terms of the incidence of adverse events and serious adverse events. For case fatality rate, Ambrisentan ( OR =0.28, 95% CI =0.11-0.74) was statistically superior to placebo and there was no statistics difference in the rest. Conclusions: The combination therapy of ERAs and PDE5i performed well in the short-term improvement of motor function. Furthermore, there was no significant difference with monotherapy in terms of safety. However, it is worth emphasizing that the choice of treatment should be based on the patient's individualized situation and the patient's requirements.